Compare Stocks: ALMS, EXEL, ARWR, and BMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$26.12 -7.5%	$25.16	$3.76 ▼ $31.35	$3.60B	-0.69	1.32 million shs	1.39 million shs
ARWR Arrowhead Pharmaceuticals	$86.01 +1.6%	$79.26	$15.01 ▼ $95.49	$11.92B	1.26	2.35 million shs	1.27 million shs
BMRN BioMarin Pharmaceutical	$59.99 0.0%	$57.58	$49.26 ▼ $66.28	$11.60B	0.24	1.59 million shs	1.84 million shs
EXEL Exelixis	$55.06 +3.8%	$53.83	$33.76 ▼ $57.57	$13.33B	0.44	2.33 million shs	4.30 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-7.54%	-3.55%	-1.43%	-0.04%	+532.45%
ARWR Arrowhead Pharmaceuticals	+1.61%	+0.56%	+2.41%	+14.79%	+439.92%
BMRN BioMarin Pharmaceutical	-0.05%	-0.46%	+1.70%	+12.68%	+3.18%
EXEL Exelixis	+3.83%	-1.34%	-1.41%	+23.95%	+47.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$26.12 -7.5%	$25.16	$3.76 ▼ $31.35	$3.60B	-0.69	1.32 million shs	1.39 million shs
ARWR Arrowhead Pharmaceuticals	$86.01 +1.6%	$79.26	$15.01 ▼ $95.49	$11.92B	1.26	2.35 million shs	1.27 million shs
BMRN BioMarin Pharmaceutical	$59.99 0.0%	$57.58	$49.26 ▼ $66.28	$11.60B	0.24	1.59 million shs	1.84 million shs
EXEL Exelixis	$55.06 +3.8%	$53.83	$33.76 ▼ $57.57	$13.33B	0.44	2.33 million shs	4.30 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-7.54%	-3.55%	-1.43%	-0.04%	+532.45%
ARWR Arrowhead Pharmaceuticals	+1.61%	+0.56%	+2.41%	+14.79%	+439.92%
BMRN BioMarin Pharmaceutical	-0.05%	-0.46%	+1.70%	+12.68%	+3.18%
EXEL Exelixis	+3.83%	-1.34%	-1.41%	+23.95%	+47.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.83	Moderate Buy	$40.30	54.29% Upside
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$96.92	12.68% Upside
BMRN BioMarin Pharmaceutical	2.71	Moderate Buy	$88.26	47.13% Upside
EXEL Exelixis	2.37	Hold	$49.50	-10.10% Downside

Current Analyst Ratings Breakdown

Latest ALMS, EXEL, ARWR, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	EXEL Exelixis	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
8/3/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$25.00
7/30/2026	ARWR Arrowhead Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$101.00 ➝ $123.00
7/27/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$100.00 ➝ $115.00
7/24/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B+) ➝ Buy (B)
7/23/2026	EXEL Exelixis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$50.00 ➝ $53.00
7/23/2026	ARWR Arrowhead Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$100.00 ➝ $120.00
7/23/2026	ARWR Arrowhead Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$110.00 ➝ $126.00
7/22/2026	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
7/22/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $115.00
7/17/2026	ARWR Arrowhead Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$88.00 ➝ $95.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$24.05M	138.46	N/A	N/A	$2.88 per share	9.07
ARWR Arrowhead Pharmaceuticals	$622.01M	19.48	$0.12 per share	708.96	$3.64 per share	23.63
BMRN BioMarin Pharmaceutical	$3.22B	3.60	$2.85 per share	21.04	$31.68 per share	1.89
EXEL Exelixis	$2.32B	5.96	$3.14 per share	17.52	$8.06 per share	6.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$1.98	N/A	N/A	N/A	-2,825.70%	-88.79%	-70.72%	8/12/2026 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.15	N/A	N/A	N/A	-48.38%	-55.09%	-18.13%	8/4/2026 (Estimated)
BMRN BioMarin Pharmaceutical	$348.90M	$1.37	43.79	10.66	0.46	8.29%	6.50%	5.07%	8/6/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.01	18.29	14.88	1.53	35.08%	39.89%	30.23%	8/5/2026 (Confirmed)

Latest ALMS, EXEL, ARWR, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALMS Alumis	-$0.7290	N/A	N/A	N/A	$3.62 million	N/A
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.9450	N/A	N/A	N/A	$932.03 million	N/A
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	N/A	N/A	N/A	$636.40 million	N/A
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.28	N/A	N/A	N/A	$44.17 million	N/A
5/14/2026	Q1 2026	ALMS Alumis	-$0.7318	-$0.74	-$0.0082	-$0.74	$2.10 million	$1.74 million
5/7/2026	Q2 2026	ARWR Arrowhead Pharmaceuticals	-$1.0950	-$0.93	+$0.1650	-$0.93	$73.84 million	$73.74 million
5/5/2026	Q1 2026	EXEL Exelixis	$0.75	$0.87	+$0.12	$0.8138	$607.51 million	$610.81 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	7.51	7.51
ARWR Arrowhead Pharmaceuticals	1.41	6.23	6.23
BMRN BioMarin Pharmaceutical	0.23	5.81	4.20
EXEL Exelixis	N/A	3.26	3.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
ARWR Arrowhead Pharmaceuticals	62.61%
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
ARWR Arrowhead Pharmaceuticals	3.60%
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	N/A	127.49 million	84.53 million	N/A
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.28 million	191.97 million	Optionable
EXEL Exelixis	1,077	251.35 million	244.82 million	Optionable

ALMS, EXEL, ARWR, and BMRN Headlines

Recent News About These Companies

Pacer Advisors Inc. Buys 308,633 Shares of Exelixis, Inc. $EXEL

August 3 at 6:15 AM | marketbeat.com

Exelixis, Inc. $EXEL Shares Acquired by Janus Henderson Group PLC

August 3 at 5:19 AM | marketbeat.com

Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Hold" by Analysts

August 3 at 4:28 AM | marketbeat.com

California State Teachers Retirement System Boosts Stock Holdings in Exelixis, Inc. $EXEL

August 3 at 3:43 AM | marketbeat.com

Cetera Investment Advisers Raises Stock Position in Exelixis, Inc. $EXEL

August 2 at 3:36 AM | marketbeat.com

Exelixis (EXEL) Slides as Investors Likely Take Profits Ahead of Earnings

July 31, 2026 | quiverquant.comQ

Exelixis, Inc. $EXEL Shares Purchased by Edgestream Partners L.P.

July 31, 2026 | marketbeat.com

Bull Harbor Capital LLC Purchases Shares of 21,258 Exelixis, Inc. $EXEL

July 31, 2026 | marketbeat.com

Lazard Asset Management LLC Raises Position in Exelixis, Inc. $EXEL

July 30, 2026 | marketbeat.com

Empowered Funds LLC Has $14.39 Million Holdings in Exelixis, Inc. $EXEL

July 30, 2026 | marketbeat.com

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

July 29, 2026 | globenewswire.com

Exelixis (EXEL) Projected to Release Quarterly Earnings on Wednesday

July 29, 2026 | marketbeat.com

OMERS ADMINISTRATION Corp Purchases 18,800 Shares of Exelixis, Inc. $EXEL

July 28, 2026 | marketbeat.com

Exelixis, Inc. $EXEL Stake Boosted by Hsbc Holdings PLC

July 26, 2026 | marketbeat.com

Entropy Technologies LP Increases Stock Position in Exelixis, Inc. $EXEL

July 26, 2026 | marketbeat.com

Dimensional Fund Advisors LP Buys 39,920 Shares of Exelixis, Inc. $EXEL

July 26, 2026 | marketbeat.com

Renaissance Technologies LLC Has $588.75 Million Stake in Exelixis, Inc. $EXEL

July 25, 2026 | marketbeat.com

Sei Investments Co. Sells 153,719 Shares of Exelixis, Inc. $EXEL

July 25, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Decreases Position in Exelixis, Inc. $EXEL

July 25, 2026 | marketbeat.com

EXEL vs. ILMN: Which Stock Is the Better Value Option?

July 24, 2026 | zacks.com

Systematic Financial Management LP Reduces Stock Holdings in Exelixis, Inc. $EXEL

July 24, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS, EXEL, ARWR, and BMRN Company Descriptions

Alumis NASDAQ:ALMS

$26.12 -2.13 (-7.54%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$26.10 -0.02 (-0.07%)

As of 08/3/2026 07:34 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$86.01 +1.36 (+1.61%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$84.49 -1.52 (-1.77%)

As of 08/3/2026 07:59 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BioMarin Pharmaceutical NASDAQ:BMRN

$59.99 -0.03 (-0.05%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$59.95 -0.04 (-0.07%)

As of 08/3/2026 08:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$55.06 +2.03 (+3.83%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$54.30 -0.77 (-1.39%)

As of 08/3/2026 07:34 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALMS, EXEL, ARWR, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALMS, EXEL, ARWR, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALMS, EXEL, ARWR, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS, EXEL, ARWR, and BMRN Company Descriptions

Alumis NASDAQ:ALMS

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALMS, EXEL, ARWR, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALMS, EXEL, ARWR, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALMS, EXEL, ARWR, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS, EXEL, ARWR, and BMRN Company Descriptions

Alumis NASDAQ:ALMS

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools